Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 16, 2019. The document serves as a transaction notification regarding a specific corporate action involving a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a single transaction involving the acquisition of American Depositary Shares (ADSs) by Mr. B McNamara, CEO of GSK Consumer Healthcare.
| Metric | Value |
|---|---|
| Instrument | American Depositary Shares (ADSs) |
| Transaction Type | Acquisition via dividend reinvestment |
| Price per ADS | $40.8259 |
| Volume | 33.216 ADSs |
| Transaction Date | April 12, 2019 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a routine transaction under the Deferred Annual Bonus Plan Post-Tax where dividends paid on April 11, 2019, were reinvested to purchase shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of an insider transaction.
Investor Verification Checklist
- Verify the total number of ADSs held by Mr. B McNamara post-transaction to assess total insider ownership.
- Confirm the dividend reinvestment terms of the Deferred Annual Bonus Plan Post-Tax.
- Review the broader GSK 20-F or quarterly reports for comprehensive financial performance data, as this 6-K does not contain it.